in its filing to the exchanges on Tuesday informed that the company has received a letter from the USFDA classifying the inspection conducted at its St. Louis facility as Official Action Indicated (OAI).
US FDA Inspected Alkem' s manufacturing facility located at St. Louis, the USA dated February 6, 2019, and March 22, 2019, the company added.
St. Louis facility contributes about 2% of the company's total US revenues or about 0.5% of the company's consolidated revenues.
"The company believes that this classification will not have any significant impact on existing supplies or the existing revenues from the operations of this facility," the company added.
Alkem Laboratories Ltd's share price is currently at Rs1,709.50, down by Rs4.05 or 0.24%, from its previous close of Rs1,713.55 on the BSE.
The scrip opened at Rs1,708.25 and has touched a high and low of Rs1,709.50 and Rs1,700.35, respectively. So far, 2,579 (NSE+BSE) shares have been traded on the counter. The current market cap of the company is Rs20,488.06cr.